Channel: Dr. John Campbell

Category: Education

Tags: human biologydiseasebiologymedical educationphysiologyhealthnursingmedicinehuman bodycampbellnclexpathophysiologynurse education

Description: Covid symptom study, another day, another record number of cases covid.joinzoe.com/data ONS latest ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights 7.56% in England (1 in 13 people) 6.97% in Wales (1 in 14 people) 6.70% in Northern Ireland (1 in 15 people) 8.57% in Scotland (1 in 12 people) Reinfection The risk of reinfection was around 10 times higher in the period when the Omicron variant was most common (20 December 2021 to 20 March 2022), compared with the period when the Delta variant was most common (17 May to 19 December 2021). UK official data coronavirus.data.gov.uk REACT – 1 Round 19 (final round) imperial.ac.uk/medicine/research-and-impact/groups/react-study/real-time-assessment-of-community-transmission-findings spiral.imperial.ac.uk/bitstream/10044/1/96170/2/REACT-1_R19_Final.pdf Community infection trends RESULTS In March 2022, prevalence was 6.37% (N=109,181), more than twice that in February 2022 Lineages determined by viral genome sequencing 3,382 (99.97%) were Omicron, 346 (10.2%) BA.1, 3035 (89.7%) BA.2 one (0.03%) BA.3 sub-lineage one (0.03%) was Delta AY.4 BA.2 Omicron sub-lineage had a growth rate advantage (compared to BA.1 and sub-lineages) of 0.11 Overall R=1.07 greatest increase in those aged 55+ years (R=1.12) prevalence (in over 55s) on March 31, 2022 was 8.31%, nearly 20-fold the median prevalence since May 1, 2020. CONCLUSIONS unprecedented levels of SARS-CoV-2 infection in England in March 2022 almost complete replacement of Omicron BA.1 by BA.2. The high and increasing prevalence in older adults may increase hospitalizations and deaths, despite high levels of vaccination. (Funded by the Department of Health and Social Care in England.) US data covid.cdc.gov/covid-data-tracker/#cases_totalcases Antibody Seroprevalence covid.cdc.gov/covid-data-tracker/#antibody-seroprevalence Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories 43.3% These percentages do not include people who have been vaccinated and have no history of infection. i.e. includes those vaccinated with a history of infection Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations) Combined seroprevalence 94.7% Infection induced seroprevalence 28.8%